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Abstract
The mobile Health offers great potential for delivery of Psycho-social Interventions. So far, the researchers have
focused mainly on efficacy, and to some extent feasibility of Psycho-social Interventions. Poor reporting of
development and initial testing has been highlighted in the recent published literature. This is not surprising
considering the lack of guidance from the national regulatory agencies in developed countries. A lack of standard
ways of development and testing of apps makes scientific evaluation of the intervention and replicability almost
impossible. Replicabiliy is an essential component of good science. We are proposing a pathway to develop, test
and report new mobile apps that deliver Psycho-social Intervention, that is based on current practices of approval of
new drugs by the US, Food and Drug Administration (FDA). This proposed process consists of modifications in the
current app development process, i.e., planning, alpha and beta testing. We are also suggesting an additional delta
stage of testing. We note the advantages and limitations in using such approach.
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Background
There has been extensive research in the use of eMedia [or more
specifically digital media (dMedia)] delivered interventions for a
variety of psychiatric disorders. Mobile apps delivering Psycho-social
Interventions fall under the term mHealth. The term “mHealth”
(mobile Health) is commonly used to describe the practice of medicine
through mobile devices that are connected to internet.
Reviews in this area have so far focused on effects of eMedia
delivered interventions using a variety of platforms [1-3]. However,
more recently the reviewers have started examining the literature for
usability, acceptability and feasibility of these interventions [4]. As far
as we are aware there is no published literature that has reported
development and initial testing of an eMedia delivered intervention in
a scientific and systematic manner. Similarly, reported literature do not
describe following a set of guidelines for quality control to develop
eMedia delivered interventions. Only a few studies report details of the
intervention developers, and an even smaller number of interventions
tested in RCTs (Randomised Controlled Trials) are available in the
public arena.
For replicability to be possible interventions should be clearly
described. Poor description of interventions threatens the potential for
good science in trials and this would seem an area of research where
pioneering trialists could leave their work difficult to replicate through
inexact descriptions of interventions. There is currently an interest in
standardizing interventions in this area, and there have been attempts
to establish criteria to self certify eMedia delivered interventions [5].
Similarly, there is an interest in evaluation of risk assessment of such
interventions [6].
Surprisingly, the regulatory agencies have not paid sufficient
attention to eMedia-delivered interventions until recently. Therefore,
only little guidance is available for clinicians or end users. The Food
and Drug Administration (FDA) released guidance recently, focusing
primarily on mHealth apps (applications) that transform the mobile
platform into a regulated medical device [7]. The remaining eMedia
will be subject to no regulation [8]. In Australia guidance is available
from the Therapeutic Goods Administration for health care
practitioners, but this is very limited [9]. The Business Standards
Institution (BSI) in England, has developed “PAS 277 Health and
wellness apps - Quality criteria across the life cycle - Code of practice”
[10] in conjunction with Innovate UK (www.innovateuk.gov.uk). There
are however, no concrete guidelines available in any of the above
systems on developing, initial testing and reporting of the mobile apps
for Psycho-social Interventions. The mHealth delivered Psycho-social
Interventions might offer unique opportunities and challenges, e.g.,
they might be delivered as stand alone interventions for common
mental health problems, without medical support or supervision.
Therefore, there is a need to develop strict protocols and quality
standards that the app developers in this area should follow.
We are suggesting possible pathway to development and testing
mobile apps for Psycho-social Interventions, using an example of drug
approval by the FDA.
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Stages of Development and Testing of Drugs
The pharmaceuticals follow fixed procedures to ensure quality of
new drugs, and in order to report its efficacy, safety and dosage. Any
new drug in the United States must go through an extensive review
and approval process by the (FDA) before it can be prescribed to
patients. A drug is any product that is meant to be used in diagnosing,
treating, or preventing diseases by affecting the structure or function of
the body. Prescription drugs, which must be obtained with the written
authorization of a licensed health care professional, are regulated by
the FDA, and some over-the-counter drugs are regulated by the FDA
as well [11].
Pre-clinical trial stage
When a substance is considered to be a potential drug, it is initially
tested in a laboratory. This is carried out in two steps. During the first
step lab studies are conducted to test the drug’s effects on living cells, as
well its toxic effects. The second step involves laboratory testing on
animals to investigate the drug’s safety, and its efficacy.
If the results of the laboratory and animal studies are encouraging,
the drug sponsor submits an IND (Investigational New Drug)
application to the FDA. The IND application summarizes information
from the laboratory and animal testing and provides a proposal for
obtaining clinical data from human patients [11]. The FDA team
reviewing the application can be composed of doctors, scientists, and
statisticians.
Clinical trial stage (safety, dosage and efficacy)
If the FDA approves the IND application, clinical trials involving
human participants start. The purpose of these trials is to test the
safety, dosage and efficacy of the new drug. Clinical trials are divided
into the following phases, although in real life one phase might test
more than one outcome,
Phase 1 trials - normally involve a small number of participants,
who are healthy volunteers. The focus is on drug safety.
Phase 2 trials - involve a reasonable number of participants with a
disease or condition and focus on optimal dose and the ability of the
drug to treat the condition.
Phase 3 trials - involve even a higher number of participants with a
disease or condition. The focus of these trials is safety and efficacy.
These trials use an RCT design and commonly compare the drug with
a placebo or a gold standard drug. These trials look into more in-depth
questions, such as effects on certain groups of patients.
Marketing Stage
Once the clinical trials are completed, the pharmaceutical submits
an NDA (New Drug Application), which requests approval of the drug
for marketing in the United States. If the drug is approved by the FDA,
the official label for the drug is written, which describes the
indications, known side effects and warnings about the product [11].
The goals of the NDA are to provide sufficient information to
permit FDA to establish the followings: [1] whether the drug is safe
and effective when used as directed? [2] are these benefits more than
the risks? [3] Is the drug’s labelling appropriate, and what information
should it contain? [4] Did the pharmaceuticals use appropriate
methods in developing, testing and reporting the drug? and [5] Does
the label tells the complete story of drug development,
psychopharmacology, toxicity etc.
Post Marketing and Effectiveness Testing
The label may be updated to include information about the drug’s
new indications and the side effects. The pharmaceutical is required to
submit safety updates, and both the prescribers and the patients can
also report serious events related to the drug to the FDA. Some drugs
are withdrawn if they cause very serious side effects. Further trials are
conducted to test the effectiveness (pragmatic trials) of the drug, to
measure the degree of beneficial effect under “real world” clinical
settings (Table 1).
 Drug development and
testing (FDA)
Mobile apps development and
testing
Suggested pathways to develop and test Psycho-social
Interventions apps
Planning and
development
Discovery of a new
substance, lab
development and initial
testing
Requirements analysis, software
design, software development, and
unit testing etc.
Involvement of health experts and patients
IND (Investigational New Drug) application
 
Clinical testing (toxicity
and efficacy)
Preclinical pharmacology
and toxicology- animal
testing
Alpha testing (within the
organization) - includes, white box,
black box and gray box testing
Alpha testing as in routine practice
 
 
 
 Clinical testing (safety,
dosage and efficacy) -
phase I, II and III trials
 
 
 
Beta testing (testing of final version
by the end user)
 
 
 
Closed beta testing (phase 1 trial) by a small number of healthy
volunteers to test the safety (side effects, privacy and security).
Preliminary data on acceptability and feasibility.
Open beta testing (phase 2 trial) to test dosage, acceptability feasibility.
Preliminary data on efficacy.
Gamma testing (phase 3 trial) - efficacy testing in an RCT against a
placebo or another app
Download statistics
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NDA (New Drug Application)
Marketing stage Drug launch with
information on label
 App launched with information about its use (See Box 1)
Post marketing stage
and effectiveness testing
Post marketing Testing
(effectiveness trial) in
routine clinical care
 Delta testing (effectiveness trials)
 Post marketing support Post marketing support, e.g.,
updates, security, functional patches
etc
Monitoring of safety in addition to providing support
Table 1: Comparison of drug and mobile apps for psycho social interventions: Development and testing.
Stages of Development and Testing of Mobile Apps
An end to end testing process begins with engaging the testing team
upfront while requirements are being defined. These should include
non-functional, regulatory and performance requirements. These
requirements must be inspected by all the stakeholders and signed off.
It is mandatory for all the participating business/engineering teams to
follow step-by-step processes, that can be summarized in following
steps;,
1. Plan and prepare (Requirement Traceability Matrix, Entry/Exit/
Success Criteria, Metrics/Measurements/Key Performance
Indicators). (Requirement inspections-These inspections should
be conducted by the business, engineering, solution architecture,
testing and implementation teams), (Requirement Tractability
Matrix-Requirements must be linked to one or more test cases as
needed. Defects must also be lined with failed test cases), (Key
Performance Indicators- definition of success and key objectives)
2. Design (Test Scenarios, Test Cases, Test Steps, Test Data)
3. Execute (Unit Testing, System Integration Testing, Performance
Testing, Business Acceptance Testing, Alpha Testing, Beta
Testing) [Unit Testing - Conducted by the engineering Team,
(System Integration Testing - Conducted by Testing Team),
(Performance Testing - Conducted by Performance Engineers to
measure an application against defined “Load Conditions”),
(Alpha Testing - Conducted by engineering/testing teams) and
(Beta Testing - Conducted by real end users)
4. Transparent reporting to all the stakeholders
5. Continuous Improvements - Improvements to the application
based on user's feedback
Pre-alpha stage
The pre-alpha stage refers to all activities performed during the
software project before testing. These activities can include
requirements analysis, software design, software development, and unit
test
Alpha testing
The alpha phase is the first step to software testing. In this phase, the
app is tested using a variety of techniques, most notably white box
techniques, that test the internal structures or workings of an app [12],
and the black box techniques that test the functionality of an app.
Additionally, the gray box testing combine both black and white box
techniques, by another testing team [13].
Beta testing
Once the app is feature complete, the beta testing is carried out. This
can reveal unknown defects or bugs. This is normally tests usability or
acceptability of the app. The process of delivering a beta version to the
users is called “beta release” and this is typically the first time that the
software is available outside of the organization that developed it.
When new features and functionality are constantly added to the app it
is called “perpetual beta”. The beta testing can either be “closed beta” in
which beta testing is done by a closed group of individuals or “open
beta” in which testing is done by a larger group.
Release of the app
Once the beta testing is complete, the app is called a release
candidate (RC) or the final product. In this stage of product
stabilization, all product features have been designed, coded and tested
through one or more beta cycles with no known “show-stopper-class
bug”. This release is also called “code complete”. Once released, the
software is generally known as the "stable release".
Support and end-of-life
During its supported lifetime, software is sometimes subjected to
service releases, or service packs, sometimes also called "interim
releases". When software is no longer sold or supported, the product is
said to have reached end-of-life.
The way forward: A proposed pathway to development and
testing of the mobile apps
We suggest a pathway to develop and test apps that deliver Psycho-
social Interventions, that can follow the following sequence;
Development stage
In addition to the steps described in pre alpha testing stage, the
initial development stage should also consider the type of the
interventions. The following types of interventions are normally
delivered by eMedia; Type 1 [An intervention delivered by a human
therapist through eMedia (e.g., telephone delivered problem solving by
a therapist, Avatar Therapy)], Type 2 [An intervention based on a
manualized, well established therapy delivered through eMedia (e.g.,
CBT delivered by a website that is based on a manual, or thought
diaries)], and, Type 3 [A new intervention that did not exist before,
and is not based on previous theory or on therapeutic principles (e.g,
electronic dispensing), or if it is, it is based loosely in theory]. It,
therefore, follows that both Type 1 and 2 interventions will require less
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rigorous testing. Although, type 1 might only be used by a therapist
(on prescription versus over the counter apps).
Preclinical Testing
Alpha testing
The process of app testing can start normally with alpha testing
(white and black box testing).
Artificial intelligence (AI) testing
Artificial Intelligence is about making machines intelligent [14].
There has been a recent increase in interest in the application of
Artificial Intelligence (AI) techniques to Software Engineering (SE)
problems. The work in this field is typified by recent advances in
Search Based Software Engineering, but also by long established work
in Probabilistic reasoning and machine learning for Software
Engineering [14]. This is an area that is full of controversies. To start
with, for example, there is no agreement on definition or function (s)
of intelligence, among scientists. There are published reports of
intelligent Real Time Therapy (iRTT), using experiential sampling
methods (ESM) [15], however, none of the available interventions in
this area can be considered intelligent using the current criteria for
artificial intelligence. This is, however an area that can be considered in
future app testing.
Clinical testing
This can typically focus on efficacy, but the secondary objectives
include, testing for dosage and safety. This stage can also include
acceptability [User Acceptance Testing (UAT) how the end user
experience the app] and feasibility [whether the intervention can be
implemented given time, financial, legal, personal, and social
constraints]. This can be divided into the following steps:
Beta testing
We recommend that Beta testing should be conducted in two stages,
i.e., closed and open beta testing.
Closed Beta testing (phase 1 trial)
This phase can involve a small number of healthy volunteers to test
the safety (side effects, privacy and security). There is evidence that
Psycho-social Interventions cause adverse outcomes [16].
Furthermore, there may be risks particular to the eMedia such as
reduction in social activities, or even addiction to eMedia [6].
However, we are not aware of published literature in this area. Delivery
through eMedia complicates and possibly increases risks, in terms of
security and privacy of data [17]. Additionally, preliminary data on
acceptability and feasibility can be collected.
Open Beta testing (Phase 2 trial)
This can typically test dosage (we believe that the concept of dosage
is important here, to offer advice on duration of the app use, in order
to avoid risks of side effects), acceptability, and feasibility. This phase
can further test efficacy by the end users in a pre and post test design.
Gamma testing (Phase 3 trials)
This phase can focus solely on efficacy using RCT design, that
compare the app with either a placebo (for example, a game app that
has no activity) or an already approved app that is known to work for
the condition being treated. Secondary objectives can include testing
safety and acceptability.
Download history and user feedback
In addition to the Phase 2 and 3 trials, the number of downloads
and feedback from the participants should be essential part of the
evaluation
Box 1: Suggested mobile app information sheet
Marketing and Post marketing stage and effectiveness trials
Once the initial testing has been carried out, the app can be
launched. The app at this stage should provide “information sheets”
similar to those provided by the drug company (Please see Box 1).
Future trials can focus on effectiveness, including cost effectiveness.
Summary
The increasing number of mobile apps requires careful
consideration of how they are developed, tested and marketed. There is
a need for professionals from both the IT and the Health background
to work jointly in these areas. Mobile apps for Psycho-social
Interventions can be developed using a process similar to the
discovery, development, testing and marketing of drugs. There are
notable differences between the two, for example the apps have a
relatively short life, compared with the drugs, due to rapid
developments in the field. This, however, also highlights a further
complication, due to an ongoing process of improvement based on
technological advances and user feedback, the app might change
radically after some time. This also means, the period for app
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development and testing should be relatively short, as compared with
testing and marketing of drugs. Researchers and clinicians might also
like to consider developing a mobile version of new Psycho-social
Interventions. However, there are some areas that need further
research. For example, the concept of safety (side effects, privacy and
security), acceptability and feasibility should be further explored.
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